EUVIMEDEUVIMED entdecken
Crossref

SGLT2 inhibitors: infection and bleeding risk after endourological prostate surgery

Marcel Schwinger, Alexander Lehmann, Vincent Scheper, Maximiliane Däuwel, Timo Egenolf, Robert Woidich, Oliver Hahn, Hubert Kübler, Charis Kalogirou

Urologia Internationalis · 17.11.2026

DOI: 10.1159/uin/aewag056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Urologia Internationalis, online erschienen am 17.11.2026. Verfasst von Marcel Schwinger und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the perioperative safety of sodium–glucose cotransporter 2 (SGLT2) inhibitor therapy in patients undergoing transurethral resection of the prostate (TUR-P) or holmium laser enucleation of the prostate (HoLEP) for benign prostatic hyperplasia, with particular focus on infectious and bleeding-related complications. Materials and Methods: This retrospective cohort study screened 258 patients undergoing TUR-P or HoLEP between January 2024 and March 2025. After exclusion of eight non-diabetic patients receiving SGLT2 inhibitors, 250 patients were included in the final analysis. Patients without diabetes mellitus served as controls (Group 1, n=150). Patients with diabetes mellitus were stratified into Group 2 (without SGLT2 inhibitors, n=50) and Group 3 (with SGLT2 inhibitors, n=50). Outcomes included postoperative urinary tract infections, bleeding-related complications, bladder tamponade, and postdischarge re-presentations within 30 days. Multivariate logistic regression analyses were adjusted for age, body mass index, age-adjusted Charlson Comorbidity Index, and duration of postoperative indwelling catheterization.

Results

Group 3 had a significantly longer hospital stay (p=0.003) and longer postoperative catheterization duration (p=0.009). Overall complications and bladder tamponade occurred more frequently in Group 3 (p=0.003 and p<0.01), but there were no significant differences regarding the need for surgical revision. Rates of postoperative urinary tract infections did not differ between groups. Postdischarge bladder tamponade was more frequent in Group 3 (p=0.03). In multivariate analyses, SGLT2 inhibitor therapy was independently associated with bleeding-related outcomes, while postoperative catheterization duration was associated with inpatient complications, inpatient bladder tamponade, and inpatient urinary tract infection.

Conclusions

Perioperative SGLT2 inhibitor therapy was not associated with increased infectious complications after TUR-P or HoLEP. An association with bleeding-related events was observed, but these findings should be interpreted cautiously given the retrospective design, limited event numbers, and wide confidence intervals in some adjusted analyses. These results support further investigation and individualized perioperative assessment of SGLT2 inhibitor therapy.

Zitieren

APA

Schwinger, M., Lehmann, A., Scheper, V., Däuwel, M., Egenolf, T., Woidich, R., Hahn, O., Kübler, H., & Kalogirou, C. (2026). SGLT2 inhibitors: infection and bleeding risk after endourological prostate surgery. Urologia Internationalis. https://doi.org/10.1159/uin/aewag056

Vancouver

Schwinger M, Lehmann A, Scheper V, Däuwel M, Egenolf T, Woidich R, et al. SGLT2 inhibitors: infection and bleeding risk after endourological prostate surgery. Urologia Internationalis. 2026. doi:10.1159/uin/aewag056

BibTeX
@article{Schwinger2026,
  author = {Schwinger, Marcel and Lehmann, Alexander and Scheper, Vincent and Däuwel, Maximiliane and Egenolf, Timo and Woidich, Robert and Hahn, Oliver and Kübler, Hubert and Kalogirou, Charis},
  title = {SGLT2 inhibitors: infection and bleeding risk after endourological prostate surgery},
  journal = {Urologia Internationalis},
  year = {2026},
  doi = {10.1159/uin/aewag056}
}
Kostenlos starten →